Publications (223) José Ignacio Fernández de Trocóniz Fernández publications

filter_list

2026

  1. A QSP Model of Valproic Acid Toxicity in Pediatric and Adult Populations: Implications for Formulation Selection and L-Carnitine Supplementation

    CPT: Pharmacometrics and Systems Pharmacology, Vol. 15, Núm. 2

  2. Design Optimization for Developing Population Pharmacokinetic Models in Critically Ill Children: Application to Teicoplanin, Piperacillin and Meropenem

    Clinical Pharmacokinetics, Vol. 65, Núm. 2, pp. 257-267

  3. Forecasting the Biological Effect of PEGylated-rHuEPO Candidates in Chronic Kidney Disease Patients using a Middle-out Translation Approach

    Pharmaceutical Research, Vol. 43, Núm. 2, pp. 381-393

  4. Leveraging in vitro Tumor Cell Killing and Cytokine Release to Predict Cytokine Release Syndrome Associated with CD3 T-cell Bispecifics in Oncology: a Retrospective Analysis

    AAPS Journal, Vol. 28, Núm. 1

2025

  1. Cortical, subcortical, brainstem and autonomic responses to nociception under total intravenous anesthesia

    Journal of Clinical Anesthesia, Vol. 103

  2. Development and Application of Physiologically-Based Pharmacokinetic Model to Predict Systemic and Organ Exposure of Colorectal Cancer Drugs

    Pharmaceutics, Vol. 17, Núm. 1

  3. Dynamics of thrombin generation: Filling the gap between the system pharmacology theory and clinical practice in clinical pharmacology and therapeutics

    Pharmacology Research and Perspectives, Vol. 13, Núm. 1

  4. Foxp3 inhibitory peptide encapsulated in a novel CD25-targeted nanoliposome promotes efficient tumor regression in mice

    Acta Pharmacologica Sinica, Vol. 46, Núm. 1, pp. 171-183

  5. Integrated Population Pharmacokinetic-pharmacodynamic Modeling of HIV Virus-host Infection Dynamics in Patients Undergoing Antiretroviral Monotherapy

    AAPS Journal, Vol. 27, Núm. 6

  6. Mechanistic PKPD modeling to describe cytokine release associated with CD3 T-cell engager therapies

    Frontiers in Immunology, Vol. 15

  7. Modeling the Interplay Between Viral and Immune Dynamics in HIV: A Review and Mrgsolve Implementation and Exploration

    Clinical and Translational Science, Vol. 18, Núm. 2

  8. Population pharmacokinetic analysis of teicoplanin in paediatric patients, including those receiving continuous kidney replacement therapy: a prospective cohort study

    Journal of Antimicrobial Chemotherapy, Vol. 80, Núm. 3, pp. 868-875

  9. Role of Antidrug Antibodies in Oncolytic Viral Therapy: A Dynamic Modelling Approach in Cancer Patients Treated with V937 Alone or in Combination

    Clinical Pharmacokinetics, Vol. 64, Núm. 10, pp. 1549-1559

  10. Towards Personalized Lymphodepletion: A Population Pharmacokinetic Fludarabine Model in Patients Receiving CAR T-Cell Therapy

    Pharmaceutics, Vol. 17, Núm. 12

2024

  1. Disentangling Anti-Tumor Response of Immunotherapy Combinations: A Physiologically Based Framework for V937 Oncolytic Virus and Pembrolizumab

    Clinical Pharmacology and Therapeutics, Vol. 116, Núm. 5, pp. 1304-1313

  2. How to use meropenem in pediatric patients undergoing CKRT? Integrated meropenem pharmacokinetic model for critically ill children

    Antimicrobial Agents and Chemotherapy, Vol. 68, Núm. 6

  3. Is estimated exposure an accurate surrogate for measured fludarabine levels in patients with CAR T-cell therapy?

    Blood Advances

  4. Mechanism-Based Modeling of Perioperative Variations in Hemoglobin Concentration in Patients Undergoing Laparoscopic Surgery

    Anesthesia and Analgesia, Vol. 138, Núm. 1, pp. 141-151

  5. Model-Based Assessment of the Liver Safety Profile of Acetaminophen to Support its Combination Use with Topical Diclofenac in Mild-to-Moderate Osteoarthritis Pain

    Pain and Therapy, Vol. 13, Núm. 1, pp. 127-143

  6. Model-Based Bioequivalence Analysis to Assess and Predict the Relative Bioavailability of Valproic Acid Formulations

    European Journal of Drug Metabolism and Pharmacokinetics, Vol. 49, Núm. 4, pp. 507-516